Prana Completes Phase IIa Alzheimer's Trial
Posted on: Thursday, 3 January 2008, 09:00 CST
Prana Biotechnology has completed Phase IIa clinical trial of PBT2 in patients with early Alzheimer's disease.
All patients have completed their final clinical assessment. The data are being analysed, and results will be delivered in the first quarter of 2008.
This Phase IIa trial is a double blind, placebo-controlled study exploring the safety and tolerability of PBT2, Prana's proprietary lead compound. The trial also measured PBT2's effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer's disease, as well as measures of cognition.
Geoffrey Kempler, chairman and CEO of Prana Biotechnology, said: "The completion of the Phase IIa trial for PBT2 represents a significant milestone in the development of Prana's innovative therapeutic platform for Alzheimer's disease, and other neurodegenerative diseases."
Source: Datamonitor
Related Articles
- Novavax Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
- ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Cytheris Initiates Asian Phase I/IIa Clinical Trial of Interleukin-7 (IL-7) As an Immunotherapy in HCV Patients
- Prana Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer's Disease
- Prana Announces Completion of Phase IIa Trial of PBT2 in Alzheimer's Disease Patients
- Prana Phase IIa Alzheimer's Disease Trial Continues
- Prana Provides Update on Phase IIa PBT2 Trial in Alzheimer's Disease Patients
- Prana to Advance Alzheimer's Drug With Phase IIa Trial
- PBT2 Phase IIa Clinical Trial in Alzheimer's Disease Patients
- Cortex Commences Enrollment in Two Additional Phase IIa Studies With AMPAKINE CX717; ADHD and Alzheimer's Disease Studies Are Underway
 |
 |
User Comments (0)
RSS Feeds